Navigation Links
CardioFocus HeartLight™ Endoscopic Ablation System Enables Treatment of Atrial Fibrillation: Live Case and Abstract Presented at EHRA EUROPACE 2011
Date:6/29/2011

MARLBOROUGH, Mass., June 29, 2011 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight™ Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announced today  that its technology was featured in a live case and scientific abstract presented at the European Heart Rhythm Association (EHRA) EUROPACE 2011 congress on June 28 in Madrid, Spain.

The case, "Atrial fibrillation ablation using laser balloon technology," demonstrated successful isolation of all pulmonary veins in a single procedure with HeartLight EAS. Presenters Vivek Y. Reddy, MD, of Mount Sinai School of Medicine, New York, USA and Petr Neuzil, MD, of Na Homolce Hospital, Prague, Czech Republic, performed the ablation on a 69-year-old male with paroxysmal AF at Na Homolce Hospital.

"The advantages offered by HeartLight EAS made it a very favorable system to address the patient's atrial fibrillation," said Dr. Reddy. "The system offers direct visualization of the heart tissue, which helped ensure contiguity of the ablation lesions. Clinical data indicates that because of this, HeartLight EAS offers an improved ability to achieve durable, reproducible PV isolation."

Additionally, an abstract presentation, "Is pure visually guided pulmonary vein isolation feasible using an endoscopic ablation system?," examined the use of HeartLight EAS in 35 patients with drug-refractory atrial fibrillation. In a single procedure, HeartLight EAS with the aid of a supplemental spiral catheter achieved an acute pulmonary vein (PV) isolation rate of 98%. Among the 18 patients completing six months follow up, 78% were in stable sinus rhythm without antiarrhythmic drugs.

"The compliant balloon catheter enables optimal visualization and tissue contact," said Julian Chun, MD, of Cardioangiologisches Centrum Bethanien, Frankfurt, Germany and one of the presenting physicians. "Physicians can use the technology to isolate all veins, regardless of individual anatomy, and with minimal repositioning for a more efficient procedure that may translate to improved PV isolation."

Stephen Sagon, President and CEO of CardioFocus Inc., commented, "The scientific sessions at EUROPACE further validate the potential benefits of HeartLight EAS in treating atrial fibrillation patients. In particular, the live case demonstrated how the system enables physicians to truly see within the heart and visually direct the application of laser energy to achieve PV isolation within a single procedure."

About CardioFocus, Inc.CardioFocus, Inc. is a medical device manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF). Its novel HeartLight Endoscopic Ablation System for catheter ablation incorporates an endoscope to provide physicians with the capacity to see within the heart, and for the first time, visually direct the application of laser energy to achieve durable pulmonary vein isolation.

The HeartLight Endoscopic Ablation System received CE Mark in 2009 for the treatment of atrial fibrillation, and is commercially available at leading institutions throughout Europe. The device is investigational in the U.S., with a pivotal study expected to commence in 2011. CardioFocus is headquartered in Marlborough, MA.  For more information on the company and its technology, please visit www.CardioFocus.com.

The scientific information discussed in this news release is preliminary and investigative. The CardioFocus HeartLight Endoscopic Ablation System is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the system. Only FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Healthcare professionals should refer to/rely upon FDA-approved labeling for the products, and not the information discussed in this news release.Company Contact:

Media Contact:Anjie Roldan

Lisa Cook  Vice President Finance

(646) 536-7012 (508) 658-7237

lcook@theruthgroup.com  aroldan@cardiofocus.com
'/>"/>

SOURCE CardioFocus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CardioFocus HeartLight™ Endoscopic Ablation System to be Featured at EHRA EUROPACE 2011
2. New Studies Support CardioFocus HeartLight™ Endoscopic Ablation Systems Notable Treatment Results for Paroxysmal Atrial Fibrillation
3. CardioFocus Secures $5M Credit Facility with Silicon Valley Bank
4. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
5. Boston Scientific Begins U.S. and International Launch of Expect™ Endoscopic Ultrasound Aspiration Needle
6. Kimberly-Clark Health Care Presents an OR-Live™ Premiere Webcast - Endoscopic Placement Method of Balloon-Retained Feeding Tubes
7. International Leaders in Electrophysiology Discuss Improving Atrial Fibrillation Treatment Using Novel Endoscopically Guided Laser Ablation Catheter
8. Practice Guidelines Confirm Utility of Endoscopic Radiofrequency Ablation (RFA) for the Treatment of Barretts Esophagus
9. MAQUET Cardiovascular Launches New VASOVIEW 6 PRO Endoscopic Vessel Harvesting System
10. Apollo Endosurgery Demonstrates Clinical Functionality of the Newly Launched OverStitch™ Endoscopic Suturing System in Bariatric Repairs and GI Therapy
11. VirtuoSaph® Plus Endoscopic Vessel Harvesting System from Terumo Continues the Advancement of the Minimally Invasive Technique for Coronary and Peripheral Artery Bypass Grafting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017  Maxor National Pharmacy Services, LLC ... it has named Leah Bailey as General ... of the company. With more than 13 ... 8 years focused on health care, Bailey joins the ... at Prime, Bailey advised the PBM, Specialty, and Mail ...
(Date:3/29/2017)... WASHINGTON , March 29, 2017  The Pharmaceutical ... regarding a new PhRMA report on patient out-of-pocket spending: ... for Medicare and Medicaid Services (CMS), the average amount ... be 13% of drug spending in 2016, down from ... is a pricing problem, not a coverage problem. Health ...
(Date:3/29/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The ablation device global market is expected to grow ... Ablation is the minimally invasive therapeutic tissue excision ... diseased tissue removal, to the removal of abnormally conducting cardiac tissue ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... Curio Wellness , a premium medical cannabis brand and trusted healthcare ... team with prominent executives from both inside and outside the cannabis industry. , ... Dumbauld , who has more than twenty years of business leadership and investment experience ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an important webinar — ... 1:00 PM ET. A recording of the webinar will also be made available following ... health and hospice companies are still popular targets for healthcare investors. This highly fragmented ...
(Date:3/29/2017)... ... 2017 , ... Immunotherapy has emerged as one of the most promising options ... be the next revolution in our fight against this complex disease. One of the ... checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single analyte ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Hills of Pittsburgh now have easier access to the robotic-assisted total-hip and ... Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently ...
(Date:3/29/2017)... ... , ... The Wharton School of the University of Pennsylvania is pleased to ... $10 million gift to establish the Ken Moelis and Julie Taffet Moelis Advance ... Wharton MBA for highly-qualified Penn undergraduates whose academic and career interests expand traditional notions ...
Breaking Medicine News(10 mins):